Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | SI | P14410 | 2/20 | 0.55 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13259354 | 0.89 | MGAM (0.67) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL8998105 | 0.86 | — | — | |
| SCHEMBL13464091 | 0.84 | TSHR (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL13242651 | 0.84 | MGAM (0.52) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL14544895 | 0.83 | MGAM (0.41) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL28004241 | 0.81 | MGAM (0.63) | MGAMGAASIMGAM2TSHR | |
| Ethylene SCHEMBL29245647 | 0.80 | MGAM (0.61) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL13209024 | 0.80 | TSHR (0.46) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL10999314 | 0.80 | MGAM (0.42) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL29235946 | 0.80 | TSHR (0.68) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985424-B2 | Dendritic polymers with enhanced amplification and interior functionality | DENDRITIC NANOTECHNOLOGIES INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985424-B2 | Dendritic polymers with enhanced amplification and interior functionality | DENDRITIC NANOTECHNOLOGIES INC. (US) | 2011-07-26 | — | — | US | disclosed |
| WO-2010028213-A2 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-4670163-A | HALOHYDROXYALKYLTHIO-SUBSTITUTED OR DIHYDROXYALKYLTHIO-SUBSTITUTED POLYCARBOXYLIC ACIDS AND SALTS | PHILLIPS PETROLEUM COMPANY (US) | 1987-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | MYD88, TLR3, TMEM97 | MGAM 3760/4885GAA 2744/4885SI 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.